(Image source from: republicworld.com)

Glenmark Pharmaceuticals Limited which is popularly known as Glenmark in association with a Canadian company SaNOtize Research and Development announced the launch of Nitric Oxide Nasal spray that can be used to treat coronavirus. The nasal spray is named FabiSpray and it can be used to treat adult patients who are at high risk. Glenmark received the marketing and manufacturing approval of FabiSpray from the Drug Controller General of India (DCGI) for NONs. Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd today confirmed the news through a statement.

The statement told "As a leading pharmaceutical player, it is important that we are an integral part of India’s fight against the COVID-19 pandemic. We are happy to receive regulatory approval for Nitric Oxide Nasal Spray (FabiSpray®) and launch it in partnership with SaNOtize. This reaffirms our commitment to providing yet another safe and effective antiviral treatment for COVID-19, and we are confident it will offer patients a much needed and timely therapy option,".

FabiSpray is designed to kill coronavirus in the upper airways. When sprayed over the nasal mucosa, it prevents the virus from spreading to the lungs. The third phase of clinical trials were conducted across 20 locations in the country on 306 patients. FabiSpray reduces the viral load told the company and there is a significant positive impact. In the current situation, NONS provide useful option to fight coronavirus in India. The Nitric Oxide Nasal spray reduces the load of virus.

By Siva Kumar